Over US$ 3.5 Bn Incremental Opportunity to be created in Lewy Body Dementia Treatment Market as Incidence of Alzheimer’s Continues Rising
Biospace,
Cholinesterase Inhibitors to Remain Most-Preferred Drug Type for Lewy Body Dementia Treatment with Revenue Surpassing US$ 2.1…